Striatal and extrastriatal atrophy in Huntington's disease and its relationship with length of the CAG repeat

Brazilian Journal of Medical and Biological Research

Volumn 39, Issue 8, 2006, Pages 1129-1136

  Ruocco, H H ^a   Lopes Cendes, I ^a   Li, L M ^a   Santos Silva, M ^a   Cendes, F ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Basal ganglia; Dynamic mutation; Genotype phenotype correlation; Huntington's disease; Magnetic resonance imaging; Neurodegeneration

Indexed keywords

ALANINE; CYSTEINE; GENOMIC DNA; GLYCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BASAL GANGLION; BRAIN ATROPHY; BRAIN SIZE; CAUDATE NUCLEUS; CHILD; CLINICAL ARTICLE; CLINICAL STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISABILITY; DISEASE DURATION; DNA DETERMINATION; FEMALE; HUMAN; HUNTINGTON CHOREA; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEOTIDE REPEAT; ONSET AGE; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PUTAMEN; TRINUCLEOTIDE REPEAT; VOLUMETRY;

EID: 33747378753     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2006000800016     Document Type: Article

References (40)

1. Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993; 72: 971-983.
2. Gusella JF, Wexler NS, Conneally PM, Naylor SL, Anderson MA, Tanzi RE, et al. A polymorphic DNA marker genetically linked to Huntington's disease. Nature 1983; 306: 234-238.
3. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson Jr EP. Neuropathological classification of Huntington's disease. J. Neuropathol Exp Neurol 1985; 44: 559-577.
4. Kassubek J, Bernhard LG, Ecker D, Juengling FD, Muche R, Schuller S, et al. Global cerebral atrophy in early stages of Huntington's disease: quantitative MRI study. Neuroreport 2004; 15: 353-365.
5. Fennema-Notestine C, Archibald SL, Jacobson MIN, Corey-Bloom J, Paulsen JS, Peavy GM, et al. In vivo evidence of cerebellar atrophy and cerebral white matter loss in Huntington disease. Neurology 2004; 63: 989-995.
6. Rosas HD, Korashetz WJ, Chen YI, Skeuse C, Vangel M, Cudkowicz ME, et al. Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology 2003; 60: 1615-1620.
7. Brandt J, Bylsma FW, Gross R, Stine OC, Ranen N, Ross CA. Trinucleotide repeat length and clinical progression in Huntington's disease. Neurology 1996; 46: 527-531.
8. Kieburtz K, MacDonald M, Shih C, Feigin A, Steinberg K, Bordwell K, et al. Trinucleotide repeat length and progression of illness in Huntington's disease. J Med Genet 1994; 31: 872-874.
9. Kremer B, Clark CM, Almqvist EW, Raymond LA, Graf P, Jacova C, at al. Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial. Neurology 1999; 53: 1000-1011.
10. Andrew SE, Goldberg YP, Kremer B, Telenius H, Theilmann J, Adam S, et al. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat Genet 1993; 4: 398-403.
11. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord 1996; 11: 136.
12. Mitchell IJ, Cooper AJ, Griffiths MR. The selective vulnerability of striatopallidal neurons. Prog Neurobiol 1999; 59: 691-719.
13. American College of Medical Genetics/American Society of Human Genetics Huntington Disease Genetic Testing Working Group. ACMG/ASHG statement. Laboratory guidelines for Huntington disease genetic testing. Am J Hum Genet 1998; 62: 1243-1247.
14. Pulsinelli WA. Selective neuronal vulnerability: morphological and molecular characteristics. Prog Brain Res 1985; 63: 29-37.
15. Beal MF, Kowall NW, Ellison DW, Mazurek MF, Swartz KJ, Martin JB. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 1986; 321: 168-171.
16. Calabresi P, Ascone CM, Centonze D, Pisani A, Sancesario G, D'Angelo, V, et al. Opposite membrane potential changes induced by glucose deprivation in striatal spiny neurons and in large aspiny intemeurons. J Neurosci 1997; 17: 1940-1949.
17. Calabresi P, Centonze D, Pisani A, Bernardi G. Metabotropic glutamate receptors and cell-type-specific vulnerability in the striatum: implication for ischemia and Huntington's disease. Exp Neurol 1999; 158: 97-108.
18. Pisani A, Bonsi P, Centonze D, Giacomini P, Calabresi P. Involvement of intracellular calcium stores during oxygen/glucose deprivation in striatal large aspiny intemeurons. J Cereb Blood Flow Metab 2000; 20: 839-846.
19. Thieben W, Duggins AJ, Good CD, Gomes L, Mahant N, Richards F, et al. The distribution of structural neuropathology in pre-clinical Huntington's disease. Brain 2002; 125: 1815-1828.
20. Aylward EH, Brandt J, Codod AM, Mangus RS, Barta PE, Harris GJ. Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at-risk persons. Neurology 1994; 44: 823-828.
21. Harris GJ, Codori AM, Lewis RF, Schmidt E, Bedi A, Brandt J. Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington's disease. Brain 1999; 122 (Pt 9): 1667-1678.
22. Penney Jr JB, Vonsattel JP, MacDonald ME, Gusella JF, Myers RH. CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol 1997; 41: 689-692.
23. Albin RL. Selective neurodegeneration in Huntington's disease. Ann Neurol 1995; 38: 835-836.
24. Kowall NM, Ferrante RJ, Martin JB. Patterns of cell loss in Huntington's disease. Trends Neurosci 1987; 10: 24-29.
25. Starkstein SE, Brandt J, Folstein S, Strauss M, McDonnell A, Folstein M. Brain atrophy in Huntington's disease: correlations with clinical and neuropsychological findings. Neurology 1988; 38 (Suppl 1): 359.
26. Grafton ST, Mazziotta JC, Pahl JJ, St George-Hyslop P, Haines JL, Gusella J, et al. Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease. Arch Neurol 1992; 49: 1161-1167.
27. Aylward EH, Codori AM, Barta PE, Pearlson GD, Harris GJ, Brandt J. Basal ganglia volume and proximity to onset in presymptomatic Huntington disease. Arch Neurol 1996; 53: 1293-1296.
28. Harris GJ, Pearlson GD, Peyser CE, Aylward EH, Roberts J, Barta PE, at al. Putamen volume reduction on magnetic resonance imaging exceeds caudate changes in mild Huntington's disease. Ann Neurol 1992; 31: 69-75.
29. de la Monte SM, Vonsattel JP, Richardson Jr EP. Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease. J Neuropathol Exp Neurol 1988; 47: 516-525.
30. Kennedy L, Shelbourne PF. Dramatic mutation instability in HD mouse striatum: does polyglutamine load contribute to call-specific vulnerability in Huntington's disease? Hum Mol Genet 2000; 9: 2539-2544.
31. Roses HD, Goodman J, Chen YI, Jenkins BG, Kennedy DN, Makris N, at al. Striatal volume loss in HD as measured by MRI and the influence of CAG repeat. Neurology 2001; 57: 1025-1028.
32. Jenkins BG, Roses HD, Chen YC, Makabe T, Myers R, MacDonald M, at al. 1H NMR spectroscopy studies of Huntington's disease: correlations with CAG repeat numbers. Neurology 1998; 50: 1357-1365.
33. Aylward EH, Li Q, Stine OC, Ranen N, Sherr M, Barta PE, at al. Longitudinal change in basal ganglia volume in patients with Huntington's disease. Neurology 1997; 48: 394-399.
34. Oyanagi K, Takeda S, Takahashi H, Ohama E, Ikuta F. A quantitative investigation of the substantia nigra in Huntington's disease. Ann Neurol 1989; 26:13-19.
35. Wexler NS, Lorimer J, Porter J, Gomez F, Moskowitz C, Shackell E, at al. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc Natl Acad Sci U S A 2004; 101: 3498-3503.
36. Sieradzan K, Mann DM, Dodge A. Clinical presentation and patterns of regional cerebral atrophy related to the length of trinucleotide repeat expansion in patients with adult onset Huntington's disease. Neurosci Lett 1997; 225: 45-48.
37. Furtado S, Suchowersky O, Rewcastle B, Graham L, Klimek ML, Garber A. Relationship between trinucleotide repeats and neuropathological changes in Huntington's disease. Ann Neurol 1996; 39: 132-136.
38. Hockly E, Cordery PM, Woodman B, Mahal A, van Dellen A, Blakemore C, at al. Environmental enrichment slows disease progression in R6/2 Huntington's disease mice. Ann Neurol 2002; 51: 235-242.
39. MacDonald ME, Vonsattel JP, Shrinidhi J, Couropmitree NN, Cupples LA, Bird ED, at al. Evidence for the GluR6 gene associated with younger onset age of Huntington's disease. Neurology 1999; 53: 1330-1332.
40. Rubinsztein DC, Leggo J, Chiano M, Dodge A, Norbury G, Rosser E, at al. Genotypes at the GluR6 kainate receptor locus are associated with variation in the age of onset of Huntington disease. Proc Natl Acad Sci U S A 1997; 94: 3872-3876.